Astellas, Yaskawa cement deal for robotic cell therapy production joint venture
Astellas Pharma and Yaskawa Electric Corporation formalized a development deal signed last year that will see the two Japanese companies invest 4.5 billion Yen ($30.4 million) into a joint venture to develop an automated cell therapy production system.
Astellas Pharma and Yaskawa Electric Corporation formalized a development deal signed last year that will see the two Japanese companies invest 4.5 billion Yen ($30.4 million) into a joint venture to develop an automated cell therapy production system.
